These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 32930141

  • 21. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
    Groenland SL, Geel DR, Janssen JM, de Vries N, Rosing H, Beijnen JH, Burgers JA, Smit EF, Huitema ADR, Steeghs N.
    Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
    [Abstract] [Full Text] [Related]

  • 22. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
    Carlson JJ, Suh K, Orfanos P, Wong W.
    Pharmacoeconomics; 2018 Apr; 36(4):495-504. PubMed ID: 29488070
    [Abstract] [Full Text] [Related]

  • 23. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 24. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
    Doménech M, Jové M, Aso S, Marín M, Nadal E.
    Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
    [Abstract] [Full Text] [Related]

  • 25. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
    Tian X, Liao Q, Yang Q, Chen L, Xiao M, Cheng Y.
    Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
    [Abstract] [Full Text] [Related]

  • 26. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 27. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
    Li H, Lai L, Wu B.
    Clin Drug Investig; 2020 Feb 01; 40(2):183-189. PubMed ID: 31820329
    [Abstract] [Full Text] [Related]

  • 28. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X, Zhu L, Zhou H, Qi C, Wang C.
    J Thorac Oncol; 2019 Sep 01; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract] [Full Text] [Related]

  • 29. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.
    Lung Cancer; 2018 Jul 01; 121():37-40. PubMed ID: 29858024
    [Abstract] [Full Text] [Related]

  • 30. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR, Loo C, Wegner EA, Nath CE, Lee S, Smith C, Lewis CR, Trahair TN, Anazodo AC.
    Pediatr Hematol Oncol; 2018 Jul 01; 35(7-8):415-421. PubMed ID: 30526220
    [Abstract] [Full Text] [Related]

  • 31. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov 01; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 32. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
    Sacdalan DB, Lucero JA.
    Cancer Treat Res Commun; 2021 Nov 01; 27():100319. PubMed ID: 33515938
    [Abstract] [Full Text] [Related]

  • 33. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E.
    Lancet Oncol; 2018 Oct 01; 19(10):e520. PubMed ID: 30245054
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
    Kashizaki F, Tanaka A, Sekido Y.
    J Med Case Rep; 2022 Aug 24; 16(1):316. PubMed ID: 35999557
    [Abstract] [Full Text] [Related]

  • 35. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.
    Zhu VW, Lu Y, Ou SI.
    Clin Lung Cancer; 2019 Jan 24; 20(1):e77-e80. PubMed ID: 30318176
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J, Gu D, Lu H, Liu S, Kong J.
    J Thorac Oncol; 2019 Dec 24; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract] [Full Text] [Related]

  • 38. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y.
    Lung Cancer; 2019 Feb 24; 128():20-25. PubMed ID: 30642448
    [Abstract] [Full Text] [Related]

  • 39. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A.
    Clin Lung Cancer; 2021 Jan 24; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract] [Full Text] [Related]

  • 40. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P, Zhang J, Shang C, Zhang L.
    Thorac Cancer; 2018 Oct 24; 9(10):1327-1332. PubMed ID: 30133144
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.